

New J-codes effective January 1, 2019

The CMS has assigned new J-codes for RITUXAN and RITUXAN HYCELA.

Rituxan[®]
Rituximab

J9312: Injection, rituximab, 10 mg
(replaces J-code J9310)

RituxanHYCELA[®]
rituximab/hyaluronidase human
subcutaneous injection | 1,400 mg/23,400 Units
| 1,600 mg/26,800 Units

J9311: Injection, rituximab 10 mg
and hyaluronidase

IMPORTANT: Please note that J-code, **J9312**, will replace J9310 for RITUXAN and the **billable units will change** from 100 mg to 10 mg.



Please confirm coding preferences with individual payers.

This coding information may assist you as you complete the payer forms for RITUXAN and RITUXAN HYCELA.

For more information about RITUXAN and RITUXAN HYCELA coding and billing, contact the payer directly, Genentech BioOncology[®] Access Solutions or your BioOncology Field Reimbursement Manager (BFRM).



The most up-to-date lists of sample codes are available at
Genentech-Access.com/RITUXAN-NHL-CLL and
Genentech-Access.com/RITUXANHYCELA.



To speak with one of our dedicated Specialists about billing and coding, call **(888) 249-4918** from 6 a.m.–5 p.m. PT, Monday through Friday.

CMS=Centers for Medicare & Medicaid Services.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech and Biogen do not make any representation or guarantee concerning reimbursement or coverage for any service or item.

RITUXAN[®], RITUXAN HYCELA[®] and their logos are registered trademarks of Biogen.

Genentech BioOncology[®] and the Access Solutions logo are registered trademarks of Genentech, Inc.

Genentech |  **Biogen**

©2018 Genentech USA, Inc., So. San Francisco, CA
and Biogen, Cambridge, MA
All rights reserved. RSC/120718/0077 12/18

ACCESS  **SOLUTIONS**[®]